WEKO3
アイテム
{"_buckets": {"deposit": "85c3c146-04e7-49c2-b6b0-be30332a5e9c"}, "_deposit": {"created_by": 2, "id": "8868", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "8868"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00008868", "sets": ["30"]}, "author_link": ["35701", "35704", "35708", "35699", "35702", "35707", "35700", "35703", "35705", "35706"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2013-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "397", "bibliographicPageStart": "387", "bibliographicVolumeNumber": "32", "bibliographic_titles": [{"bibliographic_title": "European Journal of Clinical Microbiology \u0026 Infectious Diseases"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The safety and efficacy profile of caspofungin and micafungin in Japanese patients with fungal infections were directly compared in this prospective, randomized, double-blind study. The proportion of patients who developed significant drug-related adverse event(s) (defined as a serious drug-related adverse event or a drug-related adverse event leading to study therapy discontinuation) was compared in 120 patients [caspofungin 50 mg, or 50 mg following a 70-mg loading dose on Day 1 (hereinafter, 70/50 mg) group: 60 patients; micafungin 150 mg: 60 patients]. The overall response rate was primarily evaluated in the per-protocol set (PPS) population. The proportion of patients who developed significant drug-related adverse events was 5.0 % (3/60) in the caspofungin group and 10.0 % (6/60) in the micafungin group [95 % confidence interval (CI) for the difference: -15.9 %, 5.2 %]. The favorable overall response in the PPS population for patients with esophageal candidiasis, invasive candidiasis, and chronic pulmonary aspergillosis including aspergilloma was 100.0 % (6/6), 100.0 % (3/3), and 46.7 % (14/30) in the caspofungin group, and 83.3 % (5/6), 100.0 % (1/1), and 42.4 % (14/33) in the micafungin group, respectively. In Japanese patients with Candida or Aspergillus infections, there was no statistical difference in the safety between caspofungin and micafungin. Consistent with other data on these two agents, the efficacy of caspofungin and micafungin was similar.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "European Journal of Clinical Microbiology \u0026 Infectious Diseases, 32(3), pp.387-397; 2013", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer Verlag"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s10096-012-1754-z", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© The Author(s) 2012. This article is published with open access at Springerlink.com"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "09349723", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14354373", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "35699", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Izumikawa, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "35700", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshida, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "35701", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takesue, Yoshio"}], "nameIdentifiers": [{"nameIdentifier": "35702", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oka, Shinichi"}], "nameIdentifiers": [{"nameIdentifier": "35703", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamei, Katsuhiko"}], "nameIdentifiers": [{"nameIdentifier": "35704", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Yoshitsugu"}], "nameIdentifiers": [{"nameIdentifier": "35705", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshinari, T."}], "nameIdentifiers": [{"nameIdentifier": "35706", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kartsonis, Nicholas A."}], "nameIdentifiers": [{"nameIdentifier": "35707", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Niki, Yoshihito"}], "nameIdentifiers": [{"nameIdentifier": "35708", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "EJCMID32_387.pdf", "filesize": [{"value": "217.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 217700.0, "url": {"label": "EJCMID32_387.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/8868/files/EJCMID32_387.pdf"}, "version_id": "3449c568-1ce2-441a-a97c-92fcf921067f"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "caspofungin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "micafungin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "aged", "subitem_subject_scheme": "Other"}, {"subitem_subject": "alanine aminotransferase blood level", "subitem_subject_scheme": "Other"}, {"subitem_subject": "alkaline phosphatase blood level", "subitem_subject_scheme": "Other"}, {"subitem_subject": "article", "subitem_subject_scheme": "Other"}, {"subitem_subject": "aspartate aminotransferase blood level", "subitem_subject_scheme": "Other"}, {"subitem_subject": "aspergilloma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "blood pressure", "subitem_subject_scheme": "Other"}, {"subitem_subject": "constipation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "controlled study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "double blind procedure", "subitem_subject_scheme": "Other"}, {"subitem_subject": "drug efficacy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "drug eruption", "subitem_subject_scheme": "Other"}, {"subitem_subject": "drug safety", "subitem_subject_scheme": "Other"}, {"subitem_subject": "drug withdrawal", "subitem_subject_scheme": "Other"}, {"subitem_subject": "eosinophil count", "subitem_subject_scheme": "Other"}, {"subitem_subject": "erythema", "subitem_subject_scheme": "Other"}, {"subitem_subject": "esophagus candidiasis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "eye disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "female", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gamma glutamyl transferase blood level", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gastrointestinal disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "heart atrium fibrillation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "hepatobiliary disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "human", "subitem_subject_scheme": "Other"}, {"subitem_subject": "hypertension", "subitem_subject_scheme": "Other"}, {"subitem_subject": "hypesthesia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "infection", "subitem_subject_scheme": "Other"}, {"subitem_subject": "infestation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "injection site reaction", "subitem_subject_scheme": "Other"}, {"subitem_subject": "invasive aspergillosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "invasive candidiasis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Japanese", "subitem_subject_scheme": "Other"}, {"subitem_subject": "leukocyte count", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lung aspergillosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "major clinical study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "male", "subitem_subject_scheme": "Other"}, {"subitem_subject": "multicenter study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "nausea", "subitem_subject_scheme": "Other"}, {"subitem_subject": "neurologic disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "phlebitis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "population research", "subitem_subject_scheme": "Other"}, {"subitem_subject": "potassium blood level", "subitem_subject_scheme": "Other"}, {"subitem_subject": "priority journal", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prospective study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prothrombin time", "subitem_subject_scheme": "Other"}, {"subitem_subject": "randomized controlled trial", "subitem_subject_scheme": "Other"}, {"subitem_subject": "side effect", "subitem_subject_scheme": "Other"}, {"subitem_subject": "skin disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "thrombocyte count", "subitem_subject_scheme": "Other"}, {"subitem_subject": "treatment response", "subitem_subject_scheme": "Other"}, {"subitem_subject": "vascular disease", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/31672", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-05-09"}, "publish_date": "2013-05-09", "publish_status": "0", "recid": "8868", "relation": {}, "relation_version_is_last": true, "title": ["A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis"], "weko_shared_id": -1}
A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis
http://hdl.handle.net/10069/31672
http://hdl.handle.net/10069/31672c6abb846-cfec-486d-a80e-efda68fa5e32
名前 / ファイル | ライセンス | アクション |
---|---|---|
EJCMID32_387.pdf (217.7 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-05-09 | |||||
タイトル | ||||||
タイトル | A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | caspofungin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | micafungin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | aged | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | alanine aminotransferase blood level | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | alkaline phosphatase blood level | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | article | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | aspartate aminotransferase blood level | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | aspergilloma | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | blood pressure | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | constipation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | controlled study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | double blind procedure | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | drug efficacy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | drug eruption | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | drug safety | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | drug withdrawal | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | eosinophil count | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | erythema | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | esophagus candidiasis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | eye disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | female | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | gamma glutamyl transferase blood level | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | gastrointestinal disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | heart atrium fibrillation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | hepatobiliary disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | human | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | hypertension | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | hypesthesia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | infection | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | infestation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | injection site reaction | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | invasive aspergillosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | invasive candidiasis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Japanese | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | leukocyte count | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | lung aspergillosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | major clinical study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | male | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | multicenter study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | nausea | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | neurologic disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | phlebitis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | population research | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | potassium blood level | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | priority journal | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | prospective study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | prothrombin time | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | randomized controlled trial | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | side effect | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | skin disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | thrombocyte count | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | treatment response | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | vascular disease | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kohno, Shigeru
× Kohno, Shigeru× Izumikawa, Koichi× Yoshida, Minoru× Takesue, Yoshio× Oka, Shinichi× Kamei, Katsuhiko× Miyazaki, Yoshitsugu× Yoshinari, T.× Kartsonis, Nicholas A.× Niki, Yoshihito |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The safety and efficacy profile of caspofungin and micafungin in Japanese patients with fungal infections were directly compared in this prospective, randomized, double-blind study. The proportion of patients who developed significant drug-related adverse event(s) (defined as a serious drug-related adverse event or a drug-related adverse event leading to study therapy discontinuation) was compared in 120 patients [caspofungin 50 mg, or 50 mg following a 70-mg loading dose on Day 1 (hereinafter, 70/50 mg) group: 60 patients; micafungin 150 mg: 60 patients]. The overall response rate was primarily evaluated in the per-protocol set (PPS) population. The proportion of patients who developed significant drug-related adverse events was 5.0 % (3/60) in the caspofungin group and 10.0 % (6/60) in the micafungin group [95 % confidence interval (CI) for the difference: -15.9 %, 5.2 %]. The favorable overall response in the PPS population for patients with esophageal candidiasis, invasive candidiasis, and chronic pulmonary aspergillosis including aspergilloma was 100.0 % (6/6), 100.0 % (3/3), and 46.7 % (14/30) in the caspofungin group, and 83.3 % (5/6), 100.0 % (1/1), and 42.4 % (14/33) in the micafungin group, respectively. In Japanese patients with Candida or Aspergillus infections, there was no statistical difference in the safety between caspofungin and micafungin. Consistent with other data on these two agents, the efficacy of caspofungin and micafungin was similar. | |||||
書誌情報 |
European Journal of Clinical Microbiology & Infectious Diseases 巻 32, 号 3, p. 387-397, 発行日 2013-03 |
|||||
出版者 | ||||||
出版者 | Springer Verlag | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 09349723 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14354373 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s10096-012-1754-z | |||||
権利 | ||||||
権利情報 | © The Author(s) 2012. This article is published with open access at Springerlink.com | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | European Journal of Clinical Microbiology & Infectious Diseases, 32(3), pp.387-397; 2013 |